Does the media refer more to HALO or BIIB?

In the previous week, Biogen had 3 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 17 mentions for Biogen and 14 mentions for Halozyme Therapeutics. Halozyme Therapeutics' average media sentiment score of 1.20 beat Biogen's score of 0.25 indicating that Halozyme Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Halozyme Therapeutics 9 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biogen 2 Very Positive mention(s) 2 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer UTHR or HALO?

In the previous week, United Therapeutics had 6 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 20 mentions for United Therapeutics and 14 mentions for Halozyme Therapeutics. Halozyme Therapeutics' average media sentiment score of 1.20 beat United Therapeutics' score of 0.48 indicating that Halozyme Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment United Therapeutics 10 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Halozyme Therapeutics 9 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to HALO or INCY?

In the previous week, Halozyme Therapeutics had 2 more articles in the media than Incyte. MarketBeat recorded 14 mentions for Halozyme Therapeutics and 12 mentions for Incyte. Halozyme Therapeutics' average media sentiment score of 1.20 beat Incyte's score of 0.44 indicating that Halozyme Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Halozyme Therapeutics 9 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Incyte 5 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to HALO or NBIX?

In the previous week, Neurocrine Biosciences had 3 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 17 mentions for Neurocrine Biosciences and 14 mentions for Halozyme Therapeutics. Halozyme Therapeutics' average media sentiment score of 1.20 beat Neurocrine Biosciences' score of 0.29 indicating that Halozyme Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Halozyme Therapeutics 9 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Neurocrine Biosciences 6 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to HALO or EXEL?

In the previous week, Exelixis had 27 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 41 mentions for Exelixis and 14 mentions for Halozyme Therapeutics. Halozyme Therapeutics' average media sentiment score of 1.20 beat Exelixis' score of 0.76 indicating that Halozyme Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Halozyme Therapeutics 9 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Exelixis 17 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Halozyme Therapeutics (HALO) Competitors

$69.82 +3.54 (+5.34%)

Closing price 04:00 PM Eastern

Extended Trading

$68.03 -1.79 (-2.57%)

As of 07:11 PM Eastern

Compare

HALO vs. BIIB, UTHR, INCY, NBIX, and EXEL

Should you buy Halozyme Therapeutics stock or one of its competitors? MarketBeat compares Halozyme Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Halozyme Therapeutics include Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), Neurocrine Biosciences (NBIX), and Exelixis (EXEL). These companies are all part of the "biotechnology" industry.

How does Halozyme Therapeutics compare to Biogen?

Halozyme Therapeutics (NASDAQ:HALO) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, dividends, valuation and earnings.

Halozyme Therapeutics has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market. Comparatively, Biogen has a beta of 0.2, indicating that its stock price is 80% less volatile than the broader market.

In the previous week, Biogen had 3 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 17 mentions for Biogen and 14 mentions for Halozyme Therapeutics. Halozyme Therapeutics' average media sentiment score of 1.20 beat Biogen's score of 0.25 indicating that Halozyme Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Halozyme Therapeutics	9 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biogen	2 Very Positive mention(s)	2 Positive mention(s)	11 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Halozyme Therapeutics currently has a consensus price target of $81.60, indicating a potential upside of 16.87%. Biogen has a consensus price target of $215.81, indicating a potential upside of 10.13%. Given Halozyme Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Halozyme Therapeutics is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Halozyme Therapeutics	1 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.54
Biogen	1 Sell rating(s)	13 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.52

97.8% of Halozyme Therapeutics shares are held by institutional investors. Comparatively, 87.9% of Biogen shares are held by institutional investors. 2.5% of Halozyme Therapeutics shares are held by company insiders. Comparatively, 0.3% of Biogen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Halozyme Therapeutics has a net margin of 23.13% compared to Biogen's net margin of 13.81%. Halozyme Therapeutics' return on equity of 187.91% beat Biogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Halozyme Therapeutics	23.13%	187.91%	21.92%
Biogen	13.81%	12.83%	8.01%

Biogen has higher revenue and earnings than Halozyme Therapeutics. Biogen is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Halozyme Therapeutics	$1.40B	5.93	$316.89M	$2.78	25.12
Biogen	$9.89B	2.93	$1.29B	$9.32	21.03

Summary

Halozyme Therapeutics beats Biogen on 11 of the 17 factors compared between the two stocks.

How does Halozyme Therapeutics compare to United Therapeutics?

United Therapeutics (NASDAQ:UTHR) and Halozyme Therapeutics (NASDAQ:HALO) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, earnings, valuation, dividends, profitability and media sentiment.

United Therapeutics has a net margin of 40.62% compared to Halozyme Therapeutics' net margin of 23.13%. Halozyme Therapeutics' return on equity of 187.91% beat United Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
United Therapeutics	40.62%	19.24%	17.25%
Halozyme Therapeutics	23.13%	187.91%	21.92%

United Therapeutics presently has a consensus price target of $619.42, suggesting a potential upside of 12.73%. Halozyme Therapeutics has a consensus price target of $81.60, suggesting a potential upside of 16.87%. Given Halozyme Therapeutics' higher probable upside, analysts clearly believe Halozyme Therapeutics is more favorable than United Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85
Halozyme Therapeutics	1 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.54

94.1% of United Therapeutics shares are held by institutional investors. Comparatively, 97.8% of Halozyme Therapeutics shares are held by institutional investors. 8.6% of United Therapeutics shares are held by company insiders. Comparatively, 2.5% of Halozyme Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

United Therapeutics has higher revenue and earnings than Halozyme Therapeutics. United Therapeutics is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
United Therapeutics	$3.18B	7.33	$1.33B	$27.09	20.28
Halozyme Therapeutics	$1.40B	5.93	$316.89M	$2.78	25.12

In the previous week, United Therapeutics had 6 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 20 mentions for United Therapeutics and 14 mentions for Halozyme Therapeutics. Halozyme Therapeutics' average media sentiment score of 1.20 beat United Therapeutics' score of 0.48 indicating that Halozyme Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
United Therapeutics	10 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Halozyme Therapeutics	9 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

United Therapeutics has a beta of 0.57, indicating that its share price is 43% less volatile than the broader market. Comparatively, Halozyme Therapeutics has a beta of 0.88, indicating that its share price is 12% less volatile than the broader market.

Summary

United Therapeutics beats Halozyme Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Halozyme Therapeutics compare to Incyte?

Halozyme Therapeutics (NASDAQ:HALO) and Incyte (NASDAQ:INCY) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, risk, institutional ownership and media sentiment.

In the previous week, Halozyme Therapeutics had 2 more articles in the media than Incyte. MarketBeat recorded 14 mentions for Halozyme Therapeutics and 12 mentions for Incyte. Halozyme Therapeutics' average media sentiment score of 1.20 beat Incyte's score of 0.44 indicating that Halozyme Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Halozyme Therapeutics	9 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Incyte	5 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

Incyte has higher revenue and earnings than Halozyme Therapeutics. Incyte is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Halozyme Therapeutics	$1.40B	5.93	$316.89M	$2.78	25.12
Incyte	$5.14B	3.81	$1.29B	$7.08	13.84

Incyte has a net margin of 26.71% compared to Halozyme Therapeutics' net margin of 23.13%. Halozyme Therapeutics' return on equity of 187.91% beat Incyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Halozyme Therapeutics	23.13%	187.91%	21.92%
Incyte	26.71%	26.66%	19.77%

Halozyme Therapeutics has a beta of 0.88, meaning that its stock price is 12% less volatile than the broader market. Comparatively, Incyte has a beta of 0.79, meaning that its stock price is 21% less volatile than the broader market.

97.8% of Halozyme Therapeutics shares are owned by institutional investors. Comparatively, 97.0% of Incyte shares are owned by institutional investors. 2.5% of Halozyme Therapeutics shares are owned by insiders. Comparatively, 16.2% of Incyte shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Halozyme Therapeutics presently has a consensus target price of $81.60, suggesting a potential upside of 16.87%. Incyte has a consensus target price of $104.00, suggesting a potential upside of 6.14%. Given Halozyme Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Halozyme Therapeutics is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Halozyme Therapeutics	1 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.54
Incyte	1 Sell rating(s)	12 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.36

Summary

Halozyme Therapeutics beats Incyte on 10 of the 16 factors compared between the two stocks.

How does Halozyme Therapeutics compare to Neurocrine Biosciences?

Halozyme Therapeutics (NASDAQ:HALO) and Neurocrine Biosciences (NASDAQ:NBIX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, analyst recommendations, valuation and dividends.

In the previous week, Neurocrine Biosciences had 3 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 17 mentions for Neurocrine Biosciences and 14 mentions for Halozyme Therapeutics. Halozyme Therapeutics' average media sentiment score of 1.20 beat Neurocrine Biosciences' score of 0.29 indicating that Halozyme Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Halozyme Therapeutics	9 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Neurocrine Biosciences	6 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Halozyme Therapeutics has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market. Comparatively, Neurocrine Biosciences has a beta of 0.4, meaning that its share price is 60% less volatile than the broader market.

Neurocrine Biosciences has higher revenue and earnings than Halozyme Therapeutics. Halozyme Therapeutics is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Halozyme Therapeutics	$1.40B	5.93	$316.89M	$2.78	25.12
Neurocrine Biosciences	$2.86B	5.80	$478.60M	$6.49	25.44

Halozyme Therapeutics currently has a consensus target price of $81.60, indicating a potential upside of 16.87%. Neurocrine Biosciences has a consensus target price of $187.52, indicating a potential upside of 13.58%. Given Halozyme Therapeutics' higher probable upside, equities research analysts clearly believe Halozyme Therapeutics is more favorable than Neurocrine Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Halozyme Therapeutics	1 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.54
Neurocrine Biosciences	0 Sell rating(s)	5 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.83

Halozyme Therapeutics has a net margin of 23.13% compared to Neurocrine Biosciences' net margin of 21.55%. Halozyme Therapeutics' return on equity of 187.91% beat Neurocrine Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Halozyme Therapeutics	23.13%	187.91%	21.92%
Neurocrine Biosciences	21.55%	19.79%	13.82%

97.8% of Halozyme Therapeutics shares are held by institutional investors. Comparatively, 92.6% of Neurocrine Biosciences shares are held by institutional investors. 2.5% of Halozyme Therapeutics shares are held by insiders. Comparatively, 4.6% of Neurocrine Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Neurocrine Biosciences beats Halozyme Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Halozyme Therapeutics compare to Exelixis?

Halozyme Therapeutics (NASDAQ:HALO) and Exelixis (NASDAQ:EXEL) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation, analyst recommendations and media sentiment.

Halozyme Therapeutics currently has a consensus price target of $81.60, suggesting a potential upside of 16.87%. Exelixis has a consensus price target of $47.35, suggesting a potential downside of 8.23%. Given Halozyme Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Halozyme Therapeutics is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Halozyme Therapeutics	1 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.54
Exelixis	2 Sell rating(s)	11 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.39

Exelixis has higher revenue and earnings than Halozyme Therapeutics. Exelixis is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Halozyme Therapeutics	$1.40B	5.93	$316.89M	$2.78	25.12
Exelixis	$2.32B	5.59	$782.57M	$3.01	17.14

Exelixis has a net margin of 35.08% compared to Halozyme Therapeutics' net margin of 23.13%. Halozyme Therapeutics' return on equity of 187.91% beat Exelixis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Halozyme Therapeutics	23.13%	187.91%	21.92%
Exelixis	35.08%	39.89%	30.23%

Halozyme Therapeutics has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market. Comparatively, Exelixis has a beta of 0.41, indicating that its stock price is 59% less volatile than the broader market.

97.8% of Halozyme Therapeutics shares are held by institutional investors. Comparatively, 85.3% of Exelixis shares are held by institutional investors. 2.5% of Halozyme Therapeutics shares are held by company insiders. Comparatively, 2.6% of Exelixis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Exelixis had 27 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 41 mentions for Exelixis and 14 mentions for Halozyme Therapeutics. Halozyme Therapeutics' average media sentiment score of 1.20 beat Exelixis' score of 0.76 indicating that Halozyme Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Halozyme Therapeutics	9 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Exelixis	17 Very Positive mention(s)	4 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Exelixis beats Halozyme Therapeutics on 9 of the 17 factors compared between the two stocks.

Get Halozyme Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HALO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HALO vs. The Competition

Export

Metric	Halozyme Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$7.86B	$3.28B	$6.45B	$12.42B
Dividend Yield	N/A	2.33%	2.69%	5.29%
P/E Ratio	25.12	17.93	22.30	24.19
Price / Sales	5.93	324.62	581.44	138.36
Price / Cash	13.89	116.27	42.31	57.88
Price / Book	166.24	6.63	9.84	6.72
Net Income	$316.89M	$24.20M	$3.57B	$337.19M
7 Day Performance	1.70%	-3.24%	-1.16%	0.48%
1 Month Performance	9.16%	0.53%	3.85%	5.07%
1 Year Performance	30.97%	47.24%	27.40%	34.25%

Halozyme Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HALO Halozyme Therapeutics	4.6491 of 5 stars	$69.82 +5.3%	$81.60 +16.9%	+19.1%	$7.86B	$1.40B	25.12	390	Positive News Analyst Forecast Insider Trade Analyst Revision
BIIB Biogen	3.4306 of 5 stars	$193.76 flat	$215.62 +11.3%	+44.0%	$28.61B	$9.89B	20.79	7,500
UTHR United Therapeutics	4.1953 of 5 stars	$568.43 flat	$619.42 +9.0%	+65.9%	$24.13B	$3.18B	20.98	1,400	Insider Trade
INCY Incyte	4.2141 of 5 stars	$97.16 flat	$104.00 +7.0%	+41.2%	$19.41B	$5.14B	13.72	2,844	Analyst Forecast
NBIX Neurocrine Biosciences	4.1163 of 5 stars	$156.70 flat	$185.90 +18.6%	+24.3%	$15.76B	$2.86B	24.14	2,000	Analyst Forecast Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HALO) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Halozyme Therapeutics (HALO) Competitors

HALO vs. BIIB, UTHR, INCY, NBIX, and EXEL

How does Halozyme Therapeutics compare to Biogen?

Summary

How does Halozyme Therapeutics compare to United Therapeutics?

Summary

How does Halozyme Therapeutics compare to Incyte?

Summary

How does Halozyme Therapeutics compare to Neurocrine Biosciences?

Summary

How does Halozyme Therapeutics compare to Exelixis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HALO vs. The Competition

Halozyme Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Halozyme Therapeutics (HALO) Competitors

HALO vs. BIIB, UTHR, INCY, NBIX, and EXEL

How does Halozyme Therapeutics compare to Biogen?

Which has more volatility and risk, HALO or BIIB?

Does the media refer more to HALO or BIIB?

Do analysts rate HALO or BIIB?

Do institutionals & insiders have more ownership in HALO or BIIB?

Is HALO or BIIB more profitable?

Which has better earnings and valuation, HALO or BIIB?

Summary

How does Halozyme Therapeutics compare to United Therapeutics?

Is UTHR or HALO more profitable?

Do analysts prefer UTHR or HALO?

Do insiders and institutionals believe in UTHR or HALO?

Which has preferable earnings & valuation, UTHR or HALO?

Does the media prefer UTHR or HALO?

Which has more risk and volatility, UTHR or HALO?

Summary

How does Halozyme Therapeutics compare to Incyte?

Does the media refer more to HALO or INCY?

Which has preferable valuation & earnings, HALO or INCY?

Is HALO or INCY more profitable?

Which has more risk & volatility, HALO or INCY?

Do institutionals & insiders hold more shares of HALO or INCY?

Do analysts prefer HALO or INCY?

Summary

How does Halozyme Therapeutics compare to Neurocrine Biosciences?

Does the media refer more to HALO or NBIX?

Which has more risk and volatility, HALO or NBIX?

Which has stronger earnings & valuation, HALO or NBIX?

Do analysts prefer HALO or NBIX?

Is HALO or NBIX more profitable?

Do insiders and institutionals believe in HALO or NBIX?

Summary

How does Halozyme Therapeutics compare to Exelixis?

Do analysts recommend HALO or EXEL?

Which has better earnings and valuation, HALO or EXEL?

Is HALO or EXEL more profitable?

Which has more risk and volatility, HALO or EXEL?

Do insiders & institutionals hold more shares of HALO or EXEL?

Does the media refer more to HALO or EXEL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HALO vs. The Competition

Halozyme Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools